Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Exchange Rate Effect came in at -$3.8 million in Q1 2026, down 179.29% YoY from $4.8 million in Q1 2025, and down 283.61% on a QoQ basis from $2.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 5 years of Exchange Rate Effect data on file, last reported at -$3.8 million in Q1 2026.
- Quarterly Exchange Rate Effect fell 179.29% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 469.81% YoY) and the FY2025 annual result came in at $18.0 million, up 629.77% from the prior year.
- Exchange Rate Effect fell to -$3.8 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $9.3 million in Q2 2025 to a low of -$3.8 million in Q1 2026.
- A 5-year average of $763357.1 and a median of $61000.0 in 2023 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect plunged 10850.0% — and 2025, when it surged 7943.22%.
- Tracing RXRX's Exchange Rate Effect over 5 years: stood at -$307000.0 in 2022, then surged by 140.39% to $124000.0 in 2023, then plunged by 2900.0% to -$3.5 million in 2024, then jumped by 160.11% to $2.1 million in 2025, then slumped by 283.61% to -$3.8 million in 2026.
- The last three Exchange Rate Effect figures came in at -$3.8 million (Q1 2026), $2.1 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 813,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 813,000.00 |
| Jun 30, 2026 | 813,000.00 |
| Mar 31, 2026 | -3.83 Mn |
| Mar 31, 2026 | -3.83 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Sep 30, 2024 | 403,000.00 |
| Sep 30, 2024 | 403,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Mar 31, 2024 | -219,000.00 |
| Mar 31, 2024 | -219,000.00 |